Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (June 2025)
36 slides from Biocon's investor presentation, June 2025
Slide 1: Corporate Presentation: The Multiplier Effect
Corporate Presentation The Multiplier Effect MAXIMIZING VALUE June 2025
Slide 2: Biocon Group is a global biopharmaceuticals frontrunner
Biocon Group is a global biopharmaceuticals frontrunner committed to provide equitable access to high-quality, life-saving medicines to millions of patients worldwide 2
Slide 3: Our Vision & Values
Our Vision & Values Vision To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe. Values • Value Creation through Innovation & Differentiation • Quality through Compliance & Best Practices • Integrity & Ethica
Slide 4: Biocon Group At A Glance
Biocon Group At A Glance Strategic Priorities 18,200+ 120+ Sustainable Patient v v Countries where Biocon Growth Centricity Total Employees1 products are available Drug Drug Discovery Development 1,500+ 6 Patents 1 Manufacturing Locations 2 People Focus on Power Core Capabilities Science Distributio
Slide 5: Our Business Evolution Over The Years
Our Business Evolution Over The Years FY1999 FY2004 FY2009 FY2015 FY2019 FY2025 People Revenue People Revenue Revenue People Revenue People Revenue People Revenue USD 5 USD 85 People USD 484 USD 820 USD 1.9 250 700+ 3,500+ USD 184 7,500+ 11,000+ 18,200+ mn mn mn mn mn bn 2023- 1978-1999 2000-2004 20
Slide 6: Our Global Presence
Our Global Presence Biocon London, UK Strong Footprint Across Regions Dublin, Ireland Mosta, Malta Biocon Delemont, Switzerland Biocon Delaware, U.S. T Biocon Biologics Bengaluru, India(HQ) New Jersey, U.S. London, UK Dublin, Ireland T Biocon Biologics Bad Homburg, Germany Visakhapatnam, India New J
Slide 7: Leading Global, Diversified Biopharmaceuticals Group
Leading Global, Diversified Biopharmaceuticals Group Driving Greater Health Equity Through Affordable Healthcare Products & Services Differentiated and Well-Balanced Portfolio of Generics, Biosimilars, Novel Biologics and Research & Manufacturing Services Ensuring Access through Pushing Scientific T
Slide 8: Generics Business
Generics Business
Slide 9: Generics
Generics APIs v Leadership in fermentation-based • 60+ APIs in portfolio Expanding portfolio to include APIs – Immunosuppressants, statins, • Serving 750+ API customers oncology-based HPAPIs and anti-infectives • Supplying to 100+ countries peptides, particularly GLP-1s FORMULATIONS Vertically integ
Slide 10: State-of-the-Art R&D and Manufacturing Capabilities
State-of-the-Art R&D and Manufacturing Capabilities • R&D staff: 400+ • 1st Generics Company to be approved for Liraglutide in an ICH or major regulated market • 7 Manufacturing sites (6 in India + 1 in U.S.) • 90+ cGMP approvals till date. • Key Technologies for APIs: Fermentation, Chemical Synthes
Slide 11: Balanced Portfolio of Generic APIs, Formulations
Balanced Portfolio of Generic APIs, Formulations APIs Generic Formulations Cardiovascular Cardiovascular (Atorvastatin, Dabigatran etc) Anti-Diabetics Anti-diabetic & Anti-obesity (GLP-1s: Liraglutide, Semaglutide etc) Immunosuppressants Immunosuppressants (Tacrolimus, Mycophenolic Sodium) Oncology
Slide 12: Generics Business At A Glance
Generics Business At A Glance 60+ 75+ 750+ 100+ APIs in portfolio Generic Pharma companies Countries reached Formulations in served commercially portfolio 7 90+ 8% 400+ Manufacturing cGMP approvals R&D investment as R&D Staff sites from international % of revenue regulatory agencies Note: Status as
Slide 13: Biosimilars Business
5S Biocon Biologics Biosimilars Business
Slide 14: End-to-End Capabilities Across the Biosimilars Value Chain
End-to-End Capabilities Across the Biosimilars Value Chain RESEARCH & DEVELOPMENT MANUFACTURING COMMERCIALIZATION Cutting-edge science & technology State-of-the-art facilities with Commercial reach extending across capabilities global-scale capacity 120+ countries
Slide 15: Setting New Benchmarks in Global Biosimilars Industry
Setting New Benchmarks in Global Biosimilars Industry INSULINS mAbs\rPROTEINS 2004 2020 2014 2018 World’s 1st Pichia Pastoris 1st company from India to World’s 1st bTrastuzumab 1st company globally to technology-based rh-Insulin commercialize bGlargine launched in India get U.S. FDA approval for dev
Slide 16: Robust Biosimilars Pipeline Supports Medium-term Growth
Robust Biosimilars Pipeline Supports Medium-term Growth Comprehensive Product Portfolio Across Therapy Areas Addressing a US$160 Bn Global Opportunity Therapy Area Oncology Immunology Diabetes Eye Health Bone Health Others Commercial / • bPegfilgrastim • bAdalimumab • bGlargine U100 • bTrastuzumab b
Slide 17: Fully Integrated, Global-Scale Biologics Production Capacities
Fully Integrated, Global-Scale Biologics Production Capacities • 3 state-of-the-art manufacturing sites for insulins, mAbs & conjugated rProteins (2 India, 1 Malaysia) • 90+ cGMP approvals from 25+ regulators (including U.S. FDA & EMA) • Drug Substance, Drug Product & Devices capabilities • 300+ KL
Slide 18: Center of Excellence for Insulin Production in Johor, Malaysia
Center of Excellence for Insulin Production in Johor, Malaysia • State-of-the-art integrated insulins manufacturing facility set up at an investment of over $350 million. • Facility approved by U.S. FDA, EMA, NPRA (Malaysia), TGA (Australia), ANVISA (Brazil), etc. • Invested an additional $250 milli
Slide 19: Biosimilars Value Chain: Reach in 120+ Countries
Strong Commercial Capabilities: Reach in 120+ Countries Leveraging ‘Lab to Market’ Capabilities to Address Patients’ Needs Across Geographies ✓ Bad Homburg Product Biosimilars Value Chain Development Dublin ✓ Toronto Bridgewater Clinical Trials Cambridge London New Jersey Lyon Athens Regulatory ✓ ✓
Slide 20: Biocon Biologics at a Glance
Biocon Biologics at a Glance Global Reach in Top 3 Top 15 90+ Diverse Global 120+ Global players in in Global cGMP Approvals Talent Pool of Countries rh-Insulin, Glargine1 Biomanufacturing Received from ~5,000 People Capacity2 Key Regulatory Agencies 390+ Portfolio Comprises 9 5.8+ mn Patents 20 Bio
Slide 21: Research & Manufacturing Services Business
Research & Manufacturing Services Business
Slide 22: Research Services Business
Research Services Business A Global CRDO and CMO Offering Integrated Solutions Independent publicly listed entity since 2016 Innovative R&D, Strong Technical Collaborations Manufacturing Expertise Service offerings incorporate cutting-edge Expertise and capability to deliver great Working with 400+
Slide 23: Partnered with Global Leaders in Multiple Industry Segments
Partnered with Global Leaders in Multiple Industry Segments Note: Status as of March 2024
Slide 24: Syngene at a Glance
Syngene at a Glance 2 400+ 5,600+ R&D Centers Active clients Scientists, including ~550 PhDs Twin-Engine Strategy 400+ 2.5 mn sq ft Research Services (CRO): Patents assigned to R&D and • Discovery Services clients manufacturing • Dedicated R&D Centers infrastructure Dev & Mfg Services (CDMO): • Deve
Slide 25: Novel Biologics Business
Novel Biologics Business
Slide 26: Novel Biologics
Novel Biologics • Clinical-stage biopharmaceutical company • Itolizumab, first-in-class immune-modifying mAb • Committed to bringing transformative bifunctional targeting CD6-ALCAM pathway, out-licensed to therapies for solid tumors Equillium for specific markets in 2017 • Lead asset Ficerafusp alfa
Slide 27: Financials
Financials
Slide 28: Biocon Group: Financial Highlights for FY25
Biocon Group: Financial Highlights for FY25 Rs Million FY 25 FY 24 Revenue +5% 164,699 156,212 EBITDA +5% 43,745 41,642 % margin 27% 27% PBT Before Exceptional +16% 17,901 15,368 Items PBT +24% 18,866 15,252 Net Profit -1% 10,133 10,225 Figures above are rounded off to the nearest million; % based o
Slide 29: Environment, Social, Governance
Environment, Social, Governance
Slide 30: ESG: Going Beyond Financials to Have a Positive Impact
ESG: Going Beyond Financials to Have a Positive Impact Our ESG Strategy is Focused on ‘Unconditional Equity’ Improve access to Build an empowering Adapting to Operate with integrity, Enable underserved high-quality and inclusive sustainable business transparency and communities for therapeutics to d
Slide 31: Successfully Embedding Sustainable Practices Throughout Biocon's Operations
Successfully Embedding Sustainable Practices Throughout Biocon’s Operations • S&P Global ESG Score at 69 vs 63 last year • Biocon Limited among Top 5% companies in Biotech sector • Environmental Dimension: Score: 76 | Industry max: 76 | Industry mean: 15 • Social Dimension: Score: 74 | Industry max:
Slide 32: ESG Awards & Recognitions
ESG Awards & Recognitions Enhanced FTSE4GOOD Index score to 3.6 from 3.2, Biocon Limited included in S&P Global 2025 surpassing the healthcare industry average of 2.3 and Sustainability Yearbook 3 years in a row biotech sub-industry average of 2.8 Included in DJSI EMs Index for 3 consecutive years I
Slide 33: Corporate Social Responsibility
Corporate Social Responsibility Empowering Communities Biocon Foundation’s Programs Align with Schedule VII CSR Activities as Notified Under Section 135 of the Companies Act 2013 Specialist Camps • NCD Camps Primary • Geriatric Camps Healthcare • Well Baby Camps • Dental Camps eLAJ Smart Clinics: 1+
Slide 34: Adding Value, Enhancing Skills
Adding Value, Enhancing Skills Center of Excellence for Advanced Learning in Applied Biosciences Education Partners: Claremont, California, USA Developing high-end talent for the Biotech sector PROGRAMS • Biocon-KGI Certificate Program in Biosciences • BITS Biocon Certificate Program in Applied Indu
Slide 35: People Equity: Ranked Among Top Global Pharma & Biotech Employers
People Equity: Ranked Among Top 10 Global Pharma & Biotech Employers Biocon (including Biocon Biologics) Ranked No. 9 in Top 20 Key Attributes Social Innovation Responsibility Employee Loyalty Biocon Has Been On The Top 20 Global Biotech Employers List Since 2012 Note: Science Top Employer is a Top
Slide 36: Thank You
Thank You Icon Icon Logo, icon Description automatically generated Description automatically generated Description automatically generated www.biocon.com June 2025 Biocon Group Corporate Presentation, Developed and Released by Biocon Group Global Communications Team. Write to us at: Group.Communicat